Prostate International

Papers
(The median citation count of Prostate International is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Prostate diseases and microbiome in the prostate, gut, and urine36
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer31
Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer20
Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study18
Radiation-induced haemorrhagic cystitis after prostate cancer radiotherapy: factors associated to hospitalization and treatment strategies17
Changes in diagnosis rate and treatment trends of benign prostatic hyperplasia in Korea: A nationwide population-based cohort study14
Open simple prostatectomy and robotic simple prostatectomy for large benign prostatic hyperplasia: Comparison of safety and efficacy13
A systematic review of outcomes after thermal and nonthermal partial prostate ablation12
Impact of positive surgical margin on biochemical recurrence in localized prostate cancer12
Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures12
Changing trends in robot-assisted radical prostatectomy: Inverse stage migration—A retrospective analysis11
Comparing open and robotic salvage radical prostatectomy after radiotherapy: predictors and outcomes11
Micro-Ultrasound: a way to bring imaging for prostate cancer back to urology10
Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer10
Rebiopsy rate after transperineal or transrectal prostate biopsy10
Impact of the evolving United States Preventative Services Task Force policy statements on incidence and distribution of prostate cancer over 15 years in a statewide cancer registry10
Robotic-assisted simple prostatectomy versus holmium laser enucleation of the prostate for large benign prostatic hyperplasia: A single-center preliminary study in Korea10
Robotic-assisted radical prostatectomy: learning curves and outcomes from an Australian perspective9
Risk factors associated with pain in fusion prostate biopsy9
Biparametric versus multiparametric magnetic resonance imaging of the prostate: detection of clinically significant cancer in a perfect match group9
Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer8
Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients8
Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis8
Diagnostic yield of multiparametric MRI for local recurrence at biochemical recurrence after radical prostatectomy8
RNA-seq profile of African American men with a clinically localized prostate cancer8
Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy8
Initial experience of single-port robot-assisted radical prostatectomy: A single surgeon's experience with technique description8
Topical antiseptic at time of transrectal ultrasound prostate biopsy is associated with fewer severe clinical infections and improves antibiotic stewardship8
Comparison of a combined regimen of fosfomycin and ciprofloxacin with ciprofloxacin alone as antimicrobial prophylaxis for transrectal prostate biopsy in the era of high fluoroquinolone-resistant rect8
Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?8
Minimal invasive management of bladder neck contracture using Allium round posterior stent: the long-term results7
The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy in clinically significant prostate cancer detection in patients with biopsy-naïve men according to PSA levels: A prop7
The significance of the visible tumor on preoperative magnetic resonance imaging in localized prostate cancer7
DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia7
Temporal changes of PIRADS scoring by radiologists and correlation to radical prostatectomy pathological outcomes7
Effectiveness of magnetic resonance imaging–targeted biopsy for detection of prostate cancer in comparison with systematic biopsy in our countries with low prevalence of prostate cancer: our first exp6
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer6
Artificial intelligence in urologic oncology: the actual clinical practice results of IBM Watson for Oncology in South Korea6
Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in castration-resistant prostate cancer6
Possibilities and limitations of using low biomass samples for urologic disease and microbiome research6
Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia–related lower urinary tract symptoms divided into subgroups according t6
Androgen deprivation therapy may reduce the risk of primary open-angle glaucoma in patients with prostate cancer: a nationwide population-based cohort study6
Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer6
Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels6
Factors affecting biochemical recurrence of prostate cancer after radical prostatectomy in patients with positive and negative surgical margin6
Multiparametric magnetic resonance imaging and clinical variables: Which is the best combination to predict reclassification in active surveillance patients?6
Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study5
Lifestyle habits to prevent the development of benign prostatic hyperplasia: Analysis of Japanese nationwide datasets5
Non-infectious complications following transrectal prostate needle biopsy – Outcomes from over 8000 procedures5
Does music from noise-canceling headphones have a beneficial effect on men undergoing transrectal ultrasound-guided prostate biopsy?5
Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer5
Usefulness of grayscale values measuring hypoechoic lesions for predicting prostate cancer: An experimental pilot study5
Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates5
Association between predictors of progression of benign prostatic hyperplasia and moderate-to-severe prostatitis-like symptoms: A propensity score–matched analysis5
How many cores should be taken from each region of interest when performing a targeted transrectal prostate biopsy?5
Shifting to transperineal prostate biopsy: A narrative review5
Clinical use of expanded prostate cancer index composite-based health-related quality of life outcomes after robot-assisted radical prostatectomy for localized prostate cancer5
Predictors of readmission and impact of same-day discharge in holmium laser enucleation of the prostate5
Comparison of three questionnaire forms used in the diagnosis of lower urinary tract symptoms: A prospective study5
Diagnostic accuracy of F-18-Fluorocholine PET/CT and multiparametric MRI for prostate cancer5
Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland5
Utility of multiple core biopsies during transperineal template-guided mapping biopsy for patients with large prostates and PI-RADS 1–2 on multiparametric magnetic resonance imaging4
Robotic-assisted simple prostatectomy after prostatic arterial embolization for large benign prostate hyperplasia: Initial experience4
Prostate cancer nomograms and their application in Asian men: a review4
Irreversible electroporation for prostate cancer using PSMA PET-CT4
Screening and validation of novel serum panel of microRNA in stratification of prostate cancer4
Is antibiotic prophylaxis still mandatory for transperineal prostate biopsy? Results of a comparative study4
Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study4
Retzius-sparing robotic prostatectomy is associated with higher positive surgical margin rate in anterior tumors, but not in posterior tumors, compared to conventional anterior robotic prostatectomy4
Combined α-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7–positive prostate cancer4
Dr. Answer AI for prostate cancer: Intention to use, expected effects, performance, and concerns of urologists4
The impact of conventional smoking versus electronic cigarette on the expression of VEGF, PEMPA1, and PTEN in rat prostate4
Patient age as a predictive factor in biochemical recurrence following brachytherapy: Oncological outcomes at a single center4
Impact of preoperative factors on recovery of continence after artificial urinary sphincter implantation in postprostatectomy incontinence4
Short course of dutasteride in treatment of a refractory category IIIB chronic prostatitis (A placebo-controlled study)4
A meta-analysis on the use of radiotherapy after prostatectomy: adjuvant versus early salvage radiation4
Clinical experience with active surveillance protocol using regular magnetic resonance imaging instead of regular repeat biopsy for monitoring: A study at a high-volume center in Korea4
Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer4
Current treatment patterns within 1 year after prostate cancer diagnosis in Korean patients over 75 years old: a retrospective multicenter study3
Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre3
Simplified Chinese version of the international prostate symptom score and the benign prostatic hyperplasia impact index: cross-cultural adaptation, reliability, and validity for patients with benign 3
Impact of inflammatory bowel disease on radical prostatectomy outcomes and costs of care3
Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis3
Prostate cancer trajectory-map: clinical decision support system for prognosis management of radical prostatectomy3
Conditional biochemical recurrence-free survival after radical prostatectomy in patients with high-risk prostate cancer3
Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials3
Chronological changes of lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer using SpaceOAR® system3
Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review3
A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways3
Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study3
Combination of multiparametric magnetic resonance imaging and transperineal template-guided mapping prostate biopsy to determine potential candidates for focal therapy3
Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?3
0.019890069961548